These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20932796)

  • 1. Combating evolution with intelligent design: the neoglycoside ACHN-490.
    Armstrong ES; Miller GH
    Curr Opin Microbiol; 2010 Oct; 13(5):565-73. PubMed ID: 20932796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
    Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City.
    Landman D; Kelly P; Bäcker M; Babu E; Shah N; Bratu S; Quale J
    J Antimicrob Chemother; 2011 Feb; 66(2):332-4. PubMed ID: 21131322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and spectrum of the neoglycoside ACHN-490.
    Aggen JB; Armstrong ES; Goldblum AA; Dozzo P; Linsell MS; Gliedt MJ; Hildebrandt DJ; Feeney LA; Kubo A; Matias RD; Lopez S; Gomez M; Wlasichuk KB; Diokno R; Miller GH; Moser HE
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4636-42. PubMed ID: 20805391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
    Hirokawa Y; Kinoshita H; Tanaka T; Nakata K; Kitadai N; Fujimoto K; Kashimoto S; Kojima T; Kato S
    J Med Chem; 2008 Apr; 51(7):1991-4. PubMed ID: 18330977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of Gram-negative bacterial pathogens in bloodstream infections and their resistance to antibiotics in the Czech Republic.
    Cermák P; Kolár M; Látal T
    Int J Antimicrob Agents; 2004 Apr; 23(4):401-4. PubMed ID: 15081092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species.
    Farrell DJ; Robbins M; Rhys-Williams W; Love WG
    Int J Antimicrob Agents; 2010 Jun; 35(6):531-6. PubMed ID: 20346634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.
    Ellsworth EL; Tran TP; Showalter HD; Sanchez JP; Watson BM; Stier MA; Domagala JM; Gracheck SJ; Joannides ET; Shapiro MA; Dunham SA; Hanna DL; Huband MD; Gage JW; Bronstein JC; Liu JY; Nguyen DQ; Singh R
    J Med Chem; 2006 Nov; 49(22):6435-8. PubMed ID: 17064062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New aminoglycoside antibiotics.
    Dozzo P; Moser HE
    Expert Opin Ther Pat; 2010 Oct; 20(10):1321-41. PubMed ID: 20670208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological activity of novel antibacterial quinazolines.
    Bedi PM; Kumar V; Mahajan MP
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5211-3. PubMed ID: 15380229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibacterial activity of sisomicin in comparison with gentamicin].
    Scheer M
    Arzneimittelforschung; 1976; 26(5):772-8. PubMed ID: 9099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline.
    Pankey GA
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
    Vergidis PI; Falagas ME
    Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid in vitro: mechanism and antibacterial spectrum.
    Livermore DM
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii9-16. PubMed ID: 12730138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro comparative activity of kanamycin, gentamicin and sisomicin--a new aminoglycoside, against clinical isolates.
    Lakshmi N; Kumar AG
    Indian J Pathol Microbiol; 1989 Jul; 32(3):207-12. PubMed ID: 2777351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy.
    Paterson DL
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S14-20. PubMed ID: 18713045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and antibacterial activities of neomycin-lipid conjugates: polycationic lipids with potent gram-positive activity.
    Bera S; Zhanel GG; Schweizer F
    J Med Chem; 2008 Oct; 51(19):6160-4. PubMed ID: 18778047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.